Kornimate/medical-research-clean huggingface dataset:
clinical performance of fiber reinforced frc base and bonded cad/cam resin composite endocrowns

Conditions: Dental Caries

Summary: this research proposal is introduced to clinically test short fiber reinforced flowable resin composite material (everx flow, gc europe) as a supporting base under cad/cam resin composite endocrowns due to gap of knowledge present in this area.


Eligibility criteria:
inclusion criteria: * endodontically treated molar teeth indicated for endocrown. * presence of favorable occlusion and teeth are in normal alignment with the adjacent teeth, -medically free exclusion criteria: * ▪ endodontically treated molar teeth indicated for post and core or only crown coverage. * severe periodontal problems

Keywords: restoration fracture cad/cam resin composite endocrowns lithium disilicate endocrowns
rtms as a treatment of neuropathic pain secondary to malignancy

Conditions: Malignancy

Summary: the purpose of this study isto assess the efficacy of daily 10 sessions of rtms over primary motor cortex in patients suffering from malignant neuropathic pain. thirty four patients were divided randomly into 2 groups equally using closed envelops to undergo real (20 hz, 10 second, 10 trains with inter-train interval 30 second with total pulses 2000, intensity 80% of motor threshold over hand area of motor cortex) or sham rtms (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week). patients were evaluated using a verbal descriptor scale (vds), visual analog scale (vas), leeds assessment of neuropathic symptoms and signs (lanss) and hamilton rating scale for depression (ham-d) at baseline, after 1st, 5th, 10thtreatment session, and then 15 days and 1 month after the end of treatment. ic pain.


Eligibility criteria:
inclusion criteria: all patients within age group 18-65 years with malignant lateralized neuropathic pain resistant to medical treatment for at least 2 months or associated with significant adverse effects from medication were involved in this study. exclusion criteria: patients with intracranial metallic devices patients with pacemakers or any other device. patients with recent myocardial ischemia, unstable angina patients known to have history of epilepsy.

Keywords: malignancy vas lanss vds neuropathic pain rtms motor cortex analgesia
pulsed oral sirolimus in autosomal dominant polycystic kidney disease

Conditions: Polycystic Kidney, Type 1 Autosomal Dominant Disease; Polycystic Kidney, Type 2 Autosomal Dominant Disease

Summary: sirolimus (sir) has lead to a reduction of overall kidney size, a decrease in cyst density and general tubular cell proliferation in animal models, and to a reduction of the increase in creatinine and blood urea nitrogen by 34 and 39 percent respectively, as well as a reduction of cyst proliferation, expressed by a 30 percent reduction of overall kidney enlargement, a reduction in general cyst volume, and a reduction of the cyst volume density in the renal cortex in humans. however, despite promising data from animal- and in vivo studies, most mammalian target of rapamycin inhibitor (mtor-i) studies in patients with autosomal-dominant polycystic kidney disease (adpkd) produced only subtle if any clinically relevant effects on cyst growth and the preservation of renal function. in this study we will investigate if pulsed administration of sir in a fixed weekly oral dose of 3 mg over 24 months compared to placebo significantly reduces cyst growth and preserves excretory renal function in patients with adpkd and an estimated glomerular filtration (egfr) rate below 60 ml/min per 1.73m2.


Eligibility criteria:
inclusion criteria: * adpkd, as confirmed by history, ultrasound, computed- or magnetic resonance tomography * eighteen years of age, or older * baseline egfr below 60 ml/min per 1.73m2 * negative serum pregnancy test prior to administration of sirolimus and agreement to use contraception throughout the study and three months after * written informed consent exclusion criteria: * need for renal replacement therapy * pregnancy/lactation * plans to become pregnant in the near future * refusal to use sufficient contraception * proteinuria as defined as protein:creatinine ratio \>1000 or \>1g/d, respectively * history of life threatening complications of adpkd * evidence of active systemic- or localized major infection * evidence of infiltrate or consolidation on chest x-ray * use of any investigational drug or -treatment up to 4 weeks prior to enrolment and during the study * known allergy/hypersensitivity to sirolimus and its derivatives * medication that will interfere with the cytochrome p450 (cyp3a4/cyp3a5) system * total white blood cell count below or equal to 3000/mm3 * platelet count below or equal to 100.000/mm3 * fasting triglycerides above or equal to 400 mg/dl * fasting total cholesterol above or equal to 300 mg/dl * concomitant glomerular diseases * psychiatric disorders and any condition that might prevent full comprehension of the purposes and risks of the study * history of malignancy, with the exception of adequately treated basal cell- and squamous cell carcinoma of the skin * hiv positivity

Keywords: adpkd pkd polycystic kidney disease mammalian target of rapamycin mtor-i sirolimus
post extubation dysphagia

Conditions: Severity of Aspiration in Post-extubated Subjects

Summary: the investigators hypothesize that aspiration will be more prevalent at two to four hours post-extubation but will resolve in the majority of patients by 24 to 26 hours post-extubation. the purpose of the research is to investigate whether there is a difference in swallow function two to four hours after extubation (removal of breathing tube) compared to 24 hours after extubation. this information will help healthcare providers decide if it is necessary for people to wait 24 hours after extubation before they start eating and drinking.


Eligibility criteria:
inclusion criteria: * patients that were intubated for more than 48 hours. * adults, 18 and over * all races * males and females * approval to participate in the study by the treating physician exclusion criteria: * patients with a history of oropharyngeal dysphagia. * patients with neurological disorders associated with dysphagia including dementia, parkinson's disease, multiple sclerosis, stroke, and als. * patients with a history of head and neck cancer or laryngeal surgery. * patients that are not candidate for fees because of facial fractures, nothing by mouth (npo) status for other procedures, elevated bleeding risk (patients on therapeutically dosed anticoagulant infusion or injection, platelet count less than 50,000, inr greater than 2.0, partial thromboplastin time greater than 1.5 times normal), decreased level of arousal/alertness, significant agitation, or inability to tolerate room air or nasal cannula oxygen for duration of fees. * patients who are extubated after 1400 or on weekends (friday, saturday, or sunday). * non-english speakers will be excluded

Keywords: dysphagia extubation aspiration
psychological factors in the treatment of bipolar mood disorders

Conditions: Metacognitive Capacities

Summary: the aim of this study is to trial an intervention targeting potential deficits in an individual's ability to form, and reflect upon, ideas about themselves and others (known as metacognitive capacities), specifically in relation to individuals diagnosed with a bipolar mood disorder (bmd). the proposed research will adopt a mixed qualitative and quantitative design. participants will be recruited through hospital outpatient groups (i.e., metro south addiction \& mental health services woolloongabba community health centre \& beenleigh community health centre in brisbane, queensland), and, as necessary, local non government organisations (ngos), psychiatrists, general practitioners, online support networks (sane australia, black dog institute), community mental health services(such as mindnet), and/or social media groups (facebook, twitter) supporting people who meet criteria for a bmd. the research will then use clinical interviews and quantitative (survey) methods to: (1) confirm diagnosis of participants; and (2) confirm deficits in metacognitive capacities of participants. following this, the research will then involve the implementation of an adapted intervention across a course of 12 months, aimed at improving the metacognitive capacities of participants with a diagnosis of a bmd. the research will provide an enriched understanding of a dimension of people with bmds that has not been previously explored. the research will help with gaining an understanding of the metacognitive processes of people with bmds, and inform more targeted psychological interventions.


Eligibility criteria:
inclusion criteria: * diagnosed with a bipolar affective (mood) disorder * medication has not been changed for at least the past one month * no hospitalisations in the past month * able to provide informed consent exclusion criteria: * diagnosed with an intellectual disability * diagnosed with schizoaffective disorder * high risk of suicide; defined as current, daily suicidal ideation, or the presence of a current plan and intent to commit suicide

Keywords: bipolar disorder metacognition reflective functioning metacognition-based intervention sense of self insight
validation of multiparametric models and circulating and imaging biomarkers to improve lung cancer early detection.

Conditions: Lung Cancer

Summary: clearly will focus on validation of a multifactorial "bio-radiomic" protocol for early diagnosis of lung cancer that combines circulating biomarkers and radiomic analysis. it will (a) assess the role of molecular and cellular biomarkers (exosomes, protein signatures, circulating tumor cells - ctcs, microrna) and radiomic signature, as complementary to assist early detection of lung cancer by low dose computed tomography-ldct, using bioinformatics techniques; (b) assess the prognostic role of ctcs including the role of cells epithelial mesenchymal transition (emt) and (c) standardize a method for genomic analysis of ctcs for early detection of treatment resistance.


Eligibility criteria:
inclusion criteria: * age ≥ 55 years old and exposure to smoking more than 30 packs-year; which corresponds to 6-year risk of lung cancer, calculated according to the plco score (≥ 2%). * smoker or former smoker former smokers must have ceased smoking within the 15 years prior to enrollment in the study. * absence of symptoms of lung cancer such as worsening of cough, hoarseness, hemoptysis and weight loss. exclusion criteria: * previous diagnosis of lung cancer. * positive extrapulmonary cancer history in the last 5 years (excluding in situ tumors or skin epidermoid tumor). * performing a chest ct scan in the last 18 months. * severe lung or extrapulmonary diseases that may preclude or invalidate appropriate therapy in case of diagnosis of malignant pulmonary neoplasia.
long-term results after bariatric surgery in type 1 diabetes patients

Conditions: Bariatric Surgery Status in T1D

Summary: there is a lack of long-term data on the impact of bariatric surgery in type 1 diabetes (t1d). the aim of this study is to gain long-term outcome data on the effects of bariatric surgery in obese patients with t1d.

this study aims to evaluate long-term data on the effect of bariatric surgery in t1d regarding weight lost, insulin-requirement, and quality of life. inclusion criteria are patients who underwent bariatric surgery (sleeve, one anastomosis gastric bypass, roux en y gastric bypass) and the presence of t1d prior to surgery. labor parameters include verification of t1d antibodies, and level of c-peptide. exclusion criteria is t2d. in order to obtain a sufficient number of patients for the evaluation, several sites are involved in the acquisition of these specific data.

Eligibility criteria:
inclusion criteria: * t1d-specific antibodies * c-peptide level * status after bariatric surgery exclusion criteria: * t2d * patients without t1d * patients with t1d without bariatric surgery
analysis of human als tissues and registry of als patients

Conditions: Amyotrophic Lateral Sclerosis

Summary: amyotrophic lateral sclerosis (als), often referred to as lou gehrig's disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. this devastating disorder afflicts people in the prime of their lives. at the present time, there are no cures for this disorder, and current treatments are marginal at best. despite years of intensive research, a fundamental understanding of this disease is still lacking. there is a need to identify both reliable markers of disease progression and effective treatments. the goal of this research is to bring a greater understanding of als patients closer to the research studies that can lead to new hypotheses and approaches.

patients will be approached during in-person or phone/online appointments and asked their consent to enter information and results from their physical examinations, electrodiagnostic testing, and other testing done as a standard of care and into a database to monitor disease progression and use them for research purposes. also, the patients will be asked for consent to undergo a mri scan. in a second informed consent form, patients will be enrolled to perform a rapid postmortem autopsy and have the tissue banked for research purposes. it is important to keep the consents separate because some patients may not consent to this postmortem study, but would consent to the premortem studies. the information gained from the premortem studies will be used during the postmortem examination to select tissue for further processing. tissue from different regions, including brain, spinal cord, nerve and muscle will be processed in parallel for cellular and molecular analyses that include histology, immunostaining, in situ hybridization, protein, rna, and small molecule analyses.

Eligibility criteria:
inclusion criteria: * patients over the age of 18 * established diagnosis of als * able and willing to give written informed consent and must authorize release and use of protected health information exclusion criteria: * patients below the age of 18 * no diagnosis of als

Keywords: amyotrophic lateral sclerosis (als) lou gehrig's disease neurodegenerative diseases neuromuscular diseases nervous system diseases
xlcart001 treatment in relapsed/refractory/high-risk b-cell malignancy subjects

Conditions: Lymphoma, B-Cell; Leukemia, B-cell

Summary: the trial is a single arm, single-center, non-randomized clinical trial which is designed to evaluate the efficacy and safety of xlcart001 in treatment of relapsed/refractory/high-risk b-cell malignancy subjects


Eligibility criteria:
inclusion criteria: * age ≥18 years, male and female, * confirmed as cd19-positive b cell lymphoma/leukemia by immunohistochemistry or flow cytometry * no effective treatment * patients must have a measurable or evaluable disease at the time of enrollment. * adequate organ system function including: * alt/ast \< 3 upper limit of normal; total bilirubin \< 2.5 upper limit of normal * creatinine \< 2 upper limit of normal * oxygen saturation ≥ 95% * left ventricular ejection fraction ≥ 40% * number of neutrophil ≥ 0.75×10\^9/l, number of platelet ≥ 50×10\^9/l * at least 4 weeks from receiving previous treatment (radiotherapy, chemotherapy, monoclonal antibody therapy or other treatments) * no contraindications of peripheral blood apheresis * female subjects in childbearing age, their serum or urine pregnancy test must be negative. all patients must agree to take effective contraceptive measures during the trial measures * ecog score 0-2, expected survival ≥ 12 weeks exclusion criteria: * women who are pregnant or lactating. patients have breeding intent in 12 months or cannot take effective contraceptive measures during the trial measures * uncontrollable active infection within four week. prophylactic antibiotic, antiviral and antifungal treatment is permissible. active hepatitis b or hepatitis c virus infection, as well as acquired, congenital immune deficiency diseases, including but not limited to hiv-infected persons * subjects with any autoimmune disease or any immune deficiency disease * have a history of allergy to antibodies or cellular products * participated in any other clinical trial within four weeks * used of systemic steroids within four weeks (using inhaled steroids or ≤ 20mg/d prednison are exceptions) * have mental diseases * have history of drug addiction * the investigators believe that any increase in the risk of the subject or interference with the results of the trial
music therapy for pain management for minor procedures in neonates.

Conditions: Pain

Summary: the aim of this study is to assess the effectiveness and safety of music therapy as adjuvant therapy for pain management in newborns undergoing minor painful procedures. it is a prospective study and we plan to enroll 200 healthy full term newborns undergoing minor procedures (heel pricks). they will be randomly assigned to either control or music group. those in music group will receive recorded mozart lullaby music. pain will be assessed using nips (neonatal infant pain scale) scoring tool. the potential benefit of the study would be identifying music a safe and efficient adjuvant therapy for pain management in newborns.

this randomized, controlled, double blinded, clinical trial will include full term neonates undergoing painful minor procedures (heel pricks) in the nursery unit of lincoln medical and mental health center. one of the investigators involved in the study will obtain consent from the legal guardian and enroll the participants. all infants, regardless of the group that they are assigned, will receive similar standard non-pharmacologic method of pain relief which is 0.5 ml of 24% sucrose, 2 minutes before undergoing heel prick. pacifiers will be avoided to avoid potential confounding. subjects will be randomized into two different groups. group a, music intervention group and group b, control group. in the music intervention group, a recorded instrumental lullaby music track called "deep sleep" from "bedtime mozart: classical lullabies for babies", will be played for the neonates through smart phone speakers (maximum sound up to 60 a db), starting 20 minutes before the heel prick, continuing through the procedure and for 5 minutes after the procedure. this music track has been selected based on previous research studies that showed effectiveness in neonatal pain management. an investigator involved in the study will place the baby in a bassinet in a quite, dim lighted room. he/she will play the music for those babies in the music group and will not assess the nips. another investigator wearing active noise cancelling bluetooth headphones (for blinding) will enter the room at 5 minutes prior to the procedure and assess the nips at appropriate intervals: 5 minutes prior and at 1-minute interval during and after the procedure for 5 minutes. nips will be compared using appropriate statistical methods.

Eligibility criteria:
inclusion criteria: * \>37 weeks gestation babies exclusion criteria: * \<37 weeks gestation babies * major congenital anomalies * failed hearing screen

Keywords: neonatal pain music therapy
trial to test effectiveness of depression intervention for mistreated older adults

Conditions: Depression; Depression in Old Age; Elder Abuse; Anxiety

Summary: the investigators developed em/protect, a behavioral intervention for depressed em (elderly mistreatment) victims, to work in synergy with em mistreatment resolution services that provide safety planning, support services, and links to legal services. protect is built on a model which postulates that chronic stress promotes dysfunction of the cognitive control (ccn) and reward networks, impairing the victims' ability to flexibly respond to the environment and limits their reward activities. protect therapists work with victims to develop action plans to reduce stress, and to increase rewarding experiences. em/protect has been designed in an iterative process with community em providers of the new york city (nyc) department for the aging (dfta) to use agencies' routine phq-9 depression screening and referral for service. in the current study, the investigators will compare the effectiveness of em/protect with em enriched with staff training in linking em victims to community mental health services (em/mh). the investigators intend to enroll 50 subjects that will participate in the study for approximately 12 weeks.


Eligibility criteria:
inclusion criteria: * 55 years of age or older * capacity to consent (per elder mistreatment staff) * significant depression (per elder mistreatment staff) as indicated by a score of 10 or above on the patient health questionnaire-9 (phq-9), a widely used screening tool routinely administered in elder mistreatment (em) agency settings (the phq-9 has a sensitivity of 88% and a specificity of 88% for major depression) * need for em services exclusion criteria: * active suicidal ideation (montgomery asberg depression rating scale item 10\>4) * inability to speak english or spanish * axis 1 diagnostic and statistical manual of mental disorders, 5th edition (dsm-5) diagnoses other than unipolar depression or generalized anxiety disorder (by structured clinical interview for dsm-5) * severe or life-threatening medical illness * em emergency and or referral out of em agency (per em staff)

Keywords: mental health
long-term clinical outcomes in patients with ffr guided-deferred coronary lesions, assessed by ivus analysis

Conditions: Coronary Artery Disease

Summary: this study was a multicenter retrospective study that included intravascular ultrasound (ivus) in patients with delayed stent insertion based on fractional flow reserve (ffr) in moderately narrowed coronary lesions. we would like to see the effect of lesion characteristics on clinical course.

from january 2007 to august 2014, patients who meet the criteria for selection and exclusion from keimyung university dongsan hospital, seoul national university hospital, inje university busan paik hospital, and ulsan university hospital are included. 1. target patient screening the database will select patients who meet the selection and exclusion criteria. 2. target patient characteristics the age, sex, smoking status, medical history (hypertension, diabetes mellitus, hyperlipidemia), diagnosis, and left ventricular blood count measured by echocardiography should be checked through a computerized medical record. 3. coronary angiography coronary angiography images of the subjects in the blinded state are analyzed to investigate the length of lesions, reference vessel diameter, and minimal vessel diameter. 4. intravascular ultrasound in the blinded state, the vessel's vessel area, plaque area, lumen area, etc. are measured by analyzing intravascular ultrasound images of the patient using echoplaque (indec systems, mountain view, ca).

Eligibility criteria:
inclusion criteria: * subject over 19 years old * patients with mild or moderate stenosis lesions on coronary angiography * patients with lesions with ffr values greater than 0.80 * patients with analytical intravascular ultrasound images exclusion criteria: * left main lesion * history of coronary artery bypass grafting * patients with lower left ventricular ejection fraction (\<25%)